Moreover, dabrafenib, a BRAF inhibitor which has adult indication for melanoma (all three regions) and NSCLC (the E.U. and JP) with a BRAF V600 mutation, showed a promising result in pediatric patients with BRAF V600 mutation-positive glioma in Phase I/IIa study23. This evidence concerns the gene BRAF and glioma.